tbuckley/cabot-search huggingface dataset:
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
Authors: Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, John M. Bennett, Uma Borate, Andrew M. Brunner, Wanxing Chai-Ho, Peter Curtin, Carlos M. de Castro, H. Joachim Deeg, Amy E. DeZern, Shira Dinner, Charles Foucar, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Brian A. Jonas, Sioban Keel, Yazan Madanat, Lori J. Maness, James Mangan, Shannon McCurdy, Christine McMahon, Bhumika Patel, Vishnu V. Reddy, David A. Sallman, Rory Shallis, Paul J. Shami, Swapna Thota, Asya Nina Varshavsky-Yanovsky, Peter Westervelt, Elizabeth Hollinger, Dorothy A. Shead, Cindy Hochstetler
Journal: Journal of the National Comprehensive Cancer Network (2022)

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.
Ligelizumab Improves Dermatology Quality Of Life In Patients With Chronic Spontaneous Urticaria Regardless of Angioedema Status At Baseline
Authors: Weily Soong, Jonathan Bernstein, Karl Sitz, Marcus Maurer, Ana Giménez-Arnau, Christine-Elke Ortmann, Thomas Severin
Journal: Journal of Allergy and Clinical Immunology (2022)
Coccidioidomycosis Among Persons Attending the World Championship of Model Airplane Flying--Kern County, California, October 2001
Journal: JAMA (2002)

On December 4, 2001, CDC was notified by the United Kingdom (UK) Public Health Laboratory Service (PHLS) of a UK resident aged 72 years who had culture-confirmed coccidioidomycosis (i.e., Valley fever) diagnosed in early December. During October 8-12, the patient had attended the world championship of model airplane flying in Lost Hills, California, located in Kern County in the Central Valley of California, an area where coccidioidomycosis is highly endemic (Figure 1). The patient had influenza-like symptoms on approximately October 25, 1 week after returning from Lost Hills. CDC, in collaboration with UK PHLS and the California Department of Health Services, is conducting an investigation.
MISCELLANY.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prolonged Glycemic Adaptation Following Transition From a Low- to High-Carbohydrate Diet: A Randomized Controlled Feeding Trial
Authors: Lisa T. Jansen, Nianlan Yang, Julia M.W. Wong, Tapan Mehta, David B. Allison, David S. Ludwig, Cara B. Ebbeling
Journal: Diabetes Care (2022)

Consuming ≥150 g/day carbohydrate is recommended for 3 days before an oral glucose tolerance test (OGTT) for diabetes diagnosis. For evaluation of this recommendation, time courses of glycemic changes following transition from a very-low-carbohydrate (VLC) to high-carbohydrate diet were assessed with continuous glucose monitoring (CGM).After achieving a weight loss target of 15% (±3%) on the run-in VLC diet, participants (18-50 years old, BMI ≥27 kg/m2) were randomly assigned for 10 weeks to one of three isoenergetic diets: VLC (5% carbohydrate and 77% fat); high carbohydrate, high starch (HC-Starch) (57% carbohydrate and 25% fat, including 20% refined grains); and high carbohydrate, high sugar (HC-Sugar) (57% carbohydrate and 25% fat, including 20% sugar). CGM was done throughout the trial (n = 64) and OGTT at start and end (n = 41). All food was prepared in a metabolic kitchen and consumed under observation.Glucose metrics continued to decline after week 1 in the HC-Starch and HC-Sugar groups (P < 0.05) but not VLC. During weeks 2-5, fasting and 2-h glucose (millimoles per liter per week) decreased in HC-Starch (fasting -0.10, P = 0.001; 2 h -0.10, P = 0.04). During weeks 6-9, 2-h glucose decreased in HC-Starch (-0.07, P = 0.01) and fasting and 2-h glucose decreased in HC-Sugar (fasting -0.09, P = 0.001; 2 h -0.09, P = 0.003). The number of participants with abnormal glucose tolerance by OGTT remained 10 (of 16) in VLC at start and end but decreased from 17 to 9 (of 25) in both high-carbohydrate groups.Physiological adaptation from a low- to high-carbohydrate diet may require many weeks, with implications for the accuracy of diabetes tests, interpretation of macronutrient trials, and risks of periodic planned deviations from a VLC diet.
HIV 40: inequalities fuel pandemics
Authors: None The Lancet Public Health
Journal: The Lancet Public Health (2021)

June 5 marked 40 years since the first cases of HIV were documented in the US CDC Morbidity and Mortality Weekly Report. Such a milestone offers an opportunity to reflect on progress made and barriers still to be overcome four decades on from these first reported cases in 1981. To mark this anniversary, the Lancet family of journals has commissioned and curated Lancet HIV-40, a series of reports, profiles, and interviews highlighting the strides made in HIV research, care, and prevention, and the impact of HIV/AIDS on global health and advocacy.
Reply to Shun-Fa Hung, Shyi-Chun Yii, and Shiu-Dong Chung’s Letter to the Editor re: Zhiwen Chen, Peng He, Xiaozhou Zhou, et al. Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligaments in Women with Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.11.012
Authors: Peng He, Xiaozhou Zhou, Zhiwen Chen
Journal: European Urology (2022)
S117: LONG-TERM FOLLOW UP OF DUTCH PATIENTS WITH SCD DIAGNOSED BY NEONATAL SCREENING -- EFFECT ON THE MORBIDITY AND MORTALITY IN THE NETHERLANDS.
Authors: C Vuong, L de Ligt, C de Groot-Eckhardt, H Heijboer, K Fijnvandraat
Journal: HemaSphere (2022)

Background: Newborn screening for sickle cell disease (SCD) has been introduced in January 2007 in the Netherlands. The objective of this study is to assess the effect of this neonatal screening for SCD by describing the residual risks of death and major disease-related events during the first fourteen years of life in children diagnosed with SCD at birth in the Netherlands. Aims: The objective of this study is to assess the effect of this neonatal screening for SCD by describing the residual risks of death and major disease-related events during the first fourteen years of life in children diagnosed with SCD at birth in the Netherlands. Methods: Here we report the first data of one center (Amsterdam UMC) of this prospective, national multicenter study. Following informed consent data were collected from medical files of all children born after 1 January 2007, diagnosed by neonatal screening. Descriptive data on SCD genotype, occurrence of major disease-related events (hospitalization for vaso-occlusive crisis (VOC), acute chest syndrome/pneumonia, severe infections and neurological complications) are presented. Overall survival and survival without specific SCD-related complications were analyzed by Kaplan-Meier curves. Results: Up until now, 98 (56%) out of 174 eligible subjects from this institution were included, with a total follow-up of 805 patient-years. This concerns approximately 35% of the national number. The majority (55%) had the severe genotype (HbSS/ beta0-thalassemia), the remainder had the milder genotype (HbSC or HbS/beta+-thalassemia). Survival by the age of 14 was 98.9%, with 1 death at the age of 1 years due to sepsis. Seven patients (7.1%) had a severe infection (meningitis, sepsis, osteomyelitis) caused by Streptococcus Pneumoniae in 3/7 cases. Two patients experienced a symptomatic cerebral infarction at the age of 11 months and 1.5 years. At the age of 10 years the survival without hospitalization for vaso-occlusive crisis was 27% (95% CI: 12.7 – 43.14%) and 51% (25.3 – 72.0%) for the SS/Sβ0 and SC/Sβ+ genotype respectively. Conclusion: In this cohort of neonatally screened patients with SCD, the SCD-related mortality and morbidity is still impressive with 1% mortality, 3 severe infections caused by Streptococcus Pneumoniae, and 2 patients with neurological complications. A final analysis of the effect of neonatal screening for SCD will follow after completion of data collection in all participating centers in the Netherlands. References 1. Rettenbacher et al. J Pediatr Hematol Oncol 2021; 43:7. 2. Lê et al. J Med Screen 2018. 25:2. 3. Brousse et al. J Clin Med 2019. 8:10.
Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma
Authors: Youngsic Jeon, So Mee Kwon, Hyungjin Rhee, Jeong Eun Yoo, Taek Chung, Hyun Goo Woo, Young Nyun Park
Journal: Hepatology (2022)

Background and Aims: Primary liver cancers (LCs), including HCC and intrahepatic cholangiocarcinoma (iCCA), are derived from a common developmental lineage, conferring a molecular spectrum between them. To elucidate the molecular spectrum, we performed an integrative analysis of transcriptome profiles associated with patients’ radiopathologic features. Approach and Results: We identified four LC subtypes (LC1–LC4) from RNA‐sequencing profiles, revealing intermediate subtypes between HCC and iCCA. LC1 is a typical HCC characterized by active bile acid metabolism, telomerase reverse transcriptase promoter mutations, and high uptake of gadoxetic acid in MRI. LC2 is an iCCA‐like HCC characterized by expression of the progenitor cell–like trait, tumor protein p53 mutations, and rim arterial‐phase hyperenhancement in MRI. LC3 is an HCC‐like iCCA, mainly small duct (SD) type, associated with HCC‐related etiologic factors. LC4 is further subclassified into LC4‐SD and LC4‐large duct iCCAs according to the pathological features, which exhibited distinct genetic variations (e.g., KRAS , isocitrate dehydrogenase 1/2 mutation, and FGF receptor 2 fusion), stromal type, and prognostic outcomes. Conclusions: Our integrated view of the molecular spectrum of LCs can identify subtypes associated with transcriptomic, genomic, and radiopathologic features, providing mechanistic insights into heterogeneous LC progression.
Menstruation and covid-19 vaccination
Authors: Victoria Male
Journal: BMJ (2022)

Menstruation and covid-19 vaccinationLatest evidence is limited but reassuring Victoria Male lecturer in reproductive immunologyVaccination against covid-19 provides protection against the potentially serious consequences of SARS-CoV2 infection, but as the vaccines were rolled out into younger age groups, clinicians were increasingly approached by patients worried that the vaccine had caused a change to their periods.More than 36 000 reports of menstrual changes or unexpected vaginal bleeding following covid-19 vaccination have so far been made to the yellow card surveillance scheme run by the UK Medicine and Healthcare Products Regulatory Agency (MHRA). 1 But as cycles vary naturally and the MHRA does not collect comparison data from unvaccinated people, these data cannot be used to establish whether menstrual changes increase after vaccination.A similar signal appeared in the US vaccine adverse event reporting system (VAERS), and as a result the National Institutes of Health allocated $1.67m (£1.2m; €1.4m) for research into a possible connection.
Leads from the MMWR. Case of paralytic illness associated with enterovirus 71 infection
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of COVID-19 home confinement on sleep in children: A systematic review
Authors: Lucia Rocío Camacho-Montaño, Alex Iranzo, Rosa María Martínez-Piédrola, Laura María Camacho-Montaño, Elisabet Huertas-Hoyas, Sergio Serrada-Tejeda, Cristina García-Bravo, Marta Pérez de Heredia-Torres
Journal: Sleep Medicine Reviews (2022)

Our main aim was to examine the evidence of the effects of coronavirus disease confinement on the sleep of children aged 12 years and younger. A systematic review was conducted following the recommendations for Preferred Reporting Items for Systematic Reviews and Meta-Analyses. MEDLINE, Cumulative Index for Nursing and Allied Health Literature, Excerpta Medica Database, Psychological Information Database, and Web Of Science were systematically searched between the period of January 2020 and March 2021. The quality assessment was analysed with the Newcastle-Ottawa quality assessment scale and the National Institutes of Health quality assessment tool for observational cohort and cross-sectional studies. The appraisal tool for cross-sectional studies was applied to cross-sectional studies and each longitudinal study was assessed with the critical appraisal skills programme. Data analysis was carried out through a narrative review. Eight studies were included in the review. Seven studies reported changes in sleep routines and five studies focused on sleep disturbances during confinement. The most important findings were a longer duration of sleep time, an increase in sleep latency, and daytime sleepiness. Whether or not the adverse changes to sleep patterns and bedtime routines seen during the home confinement period have any long-term consequences for children's sleep and daytime functioning remains unknown.
Commentary
Authors: Klaus Mergener
Journal: Endoscopy (2022)

Endoscopists need a large toolbox and the ability to improvise depending on the patient’s therapeutic needs. Active diverticular bleeding has been managed with injection, cautery, clipping, and banding. High quality evidence to tell us which technique is best is lacking, but guidelines suggest the use of clipping or banding if feasible [1]. However, the attachments needed for banding or cap-mounted clips compromise visibility and maneuverability of the endoscope, and delayed perforation and early rebleeding have been reported.
The peroxisome proliferator-activated receptor agonist rosiglitazone specifically represses tumour metastatic potential in chromatin inaccessibility-mediated FABP4-deficient gastric cancer
Authors: Qi-Yue Chen, Xiao-Bo Huang, Ya-Jun Zhao, Hua-Gen Wang, Jia-Bin Wang, Li-Chao Liu, Ling-Qian Wang, Qing Zhong, Jian-Wei Xie, Jian-Xian Lin, Jun Lu, Long-Long Cao, Mi Lin, Ru-Hong Tu, Chao-Hui Zheng, Ping Li, Chang-Ming Huang
Journal: Theranostics (2022)

Background: Efforts to prevent recurrence in gastric cancer (GC) patients are limited by current incomplete understanding of the pathological mechanisms.The present study aimed to identify novel tumour metastasis-associated genes and investigate potential value of these genes in clinical diagnosis and therapy.Methods: RNA sequencing was performed to identify differentially expressed genes related to GC metastasis.The expression and prognostic significance of fatty acid binding protein 4 (FABP4) were evaluated in two independent cohorts of GC patients.Chromatin immunoprecipitation sequencing, diverse mouse models and assays for transposase-accessible chromatin with high-throughput sequencing were used to investigate the roles and mechanisms of action of FABP4. Results:The results of the present multicentre study confirmed an association between a decrease in the expression of FABP4 and poor outcomes in GC patients.FABP4 inhibited GC metastasis but did not influence tumour growth in vitro and in vivo.Mechanistically, FABP4 binding with peroxisome proliferator-activated receptor γ (PPAR-γ) facilitated the translocation of PPAR-γ to the nucleus.FABP4 depletion suppressed PPAR-γ-mediated transcription of cell adhesion molecule 3 (CADM3), which preferentially governed GC metastasis.Notably, the PPAR-γ agonist rosiglitazone reversed the metastatic properties of FABP4-deficient GC cells in vitro and demonstrated viable therapeutic potential in multiple mouse models.For GC patients with diabetes, low FABP4 portends better prognosis than high FABP4 after receipt of rosiglitazone treatment.Additionally, chromatin inaccessibility induced by HDAC1 reduced FABP4 expression at the epigenetic level.Conclusions: Our findings suggest that chromatin inaccessibility orchestrates a reduction in FABP4 expression, which inhibits CADM3 transcription via PPAR-γ, thereby resulting in GC metastasis.The antidiabetic drug rosiglitazone restores PPAR-γ/CADM3 activation in FABP4-deficient GC and thus has promising therapeutic potential.
Kidney donor cards.
Journal: BMJ (1973)

primary site disease in the sigmoid (skip lesions); disease in an unsually long segment of bowel; and linear confluent intramural ulceration due to a fistulous track running parallel to the bowel lumen.'5In practice it is inmportant to distinguish between the two conditions.Routine segmental resection of the sigmoid leads to a high incidence of postoperative complications in Crohn's disease.The most common are delay in wound healing, disruption of the anastomosis with fistula formation and dis- charging abdominal sinuses, recto-vaginal fistula, and chronic anal fissure or fistula.There is also a high incidence of recurrent disease in the remaining colon or rectum, with consequent symptomatic relapse.Correct diagnosis will pre- vent the complications of inadequate surgical treatment and encourage a more determined course of medical treatment, including the use of corticosteroids.
FDA Approves First KRAS Inhibitor: Sotorasib
Journal: Cancer Discovery (2021)

The FDA has approved the first KRAS-targeted therapy, sotorasib, for patients with previously treated non-small cell lung cancer with KRASG12C mutations. In a phase II trial, the drug yielded a median progression-free survival of 6.8 months in patients whose disease had advanced despite treatment with standard therapies, namely platinum-based chemotherapy and PD-1-PD-L1 inhibitors.
Short-Acting Opioids for Hospitalized Patients With Opioid Use Disorder
Authors: Ashish P. Thakrar
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2022 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Medical News
Journal: JAMA (1927)

(Physicians will confer a favor by sending for this department items of news of more or less general interest: such as relate to society activities, new hospitals, education, public health, etc.) <h3>ALABAMA</h3><h3>Radium Recovered After Passing Through Furnace.</h3> — A tube of radium, valued at $4,500, was lost about June 1, at the Coffee Hospital, Sheffield, and after an intensive search was found by means of an electroscope in the city dump. The radium had passed through the furnace at the garbage disposal plant, and had been buried in the refuse about three weeks. The search was conducted by an insurance company which had insured the hospital against the loss of the radium. <h3>ARKANSAS</h3><h3>Personal.</h3> —The governor has appointed Drs. William W. Verser, Harrisburg, William W. York, Ashdown, and William A. Montgomery, Atkins, to fill the vacancies on the board of medical examiners of the Arkansas Medical Society.— Dr. Joseph
COVID-19 Vaccination Coverage and Vaccine Confidence by Sexual Orientation and Gender Identity — United States, August 29–October 30, 2021
Authors: A.D. McNaghten, Noel T. Brewer, Mei-Chuan Hung, Peng-Jun Lu, Demetre Daskalakis, Neetu Abad, Jennifer Kriss, Carla Black, Elisabeth Wilhelm, James T. Lee, Adi Gundlapalli, Janet Cleveland, Laurie Elam-Evans, Kimberly Bonner, James Singleton
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

Vaccination was defined as receipt of ≥1 dose of BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), or other COVID-19 vaccine, or 1 dose of Ad.26.COV2.S (Janssen [Johnson & Johnson]) COVID-19 vaccine.† Survey weights were calibrated to match the number of persons reported in each jurisdiction by sex and age group as of mid-month, as reported by jurisdictions to CDC. § Response rate was calculated according to the American Association for Public